
|Slideshows|May 18, 2018
EMPA-REG OUTCOME: Analysis in Women with T2DM and CVD
Author(s)Veronica Hackenthal, MD
A recent trial found that empagliflozin can reduce the risk of cardiovascular deaths in type 2 diabetes patients; are results similar in men and women?
Advertisement
  Â
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Alpha-Gal Syndrome: Closing an Underrecognized Allergy Diagnostic Gap
2
Pelacarsen Misses Primary Endpoint in Lp(a)HORIZON Phase 3 Trial
3
GRI-0621 Improves FVC, Reduces Fibrotic Biomarkers in IPF
4
ORFAN-MAESTRIA: AI Predicts Cardioembolic Stroke, Atrial Fibrillation from CT Scans
5






























































